In This Article:
-
Quarterly Revenue: INR559 crores, a 19% year-on-year growth.
-
Adjusted EBITDA Margin: 16.45% for Q3 FY25.
-
Adjusted EBITDA: INR92.3 crores, a 15% year-on-year growth.
-
PAT Growth: 23% year-on-year.
-
Oncology Business Growth: 24% post-MG Hospital Vizag acquisition.
-
Emerging Centers Growth: 25% year-on-year.
-
Kolkata Centers Growth: 40% year-on-year.
-
South Mumbai Center Growth: 28% year-on-year.
-
9-Month Revenue: INR1,638 crores, a 15% growth year-on-year.
-
Core HCG Centers Revenue Growth: 21% year-on-year, excluding Milann.
-
Core HCG Centers EBITDA Growth: 15% year-on-year, with a 20% EBITDA margin.
-
MG Hospital Contribution: INR25 crores with a 24% margin.
-
OPD Footfall Increase: 9% year-on-year.
-
Chemotherapy Sessions Growth: 19% year-on-year.
-
LINAC Machine Utilization: 60% capacity utilization.
-
Bed Occupancy Rate: Improved from 52% to 55% year-on-year.
-
Established Centers Revenue Growth: 20% year-on-year.
-
Established Centers EBITDA Growth: 14% year-on-year.
-
Emerging Centers EBITDA Growth: 65% year-on-year.
-
ARPOB Growth: 3.5%, standing at INR44,284.
-
Capital Expenditure: Estimated at INR275 crores for the year, with INR172 crores deployed.
-
Effective Tax Rate: 3% for 9 months ended December 31, 2024.
Release Date: February 20, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
HealthCare Global Enterprises Ltd (NSE:HCG) reported its highest-ever quarterly revenue of INR559 crores, marking a 19% year-on-year growth.
-
The company achieved a 23% growth in PAT and a 15% growth in adjusted EBITDA, indicating strong financial performance.
-
The Oncology business, post-MG Hospital Vizag acquisition, grew by 24%, enhancing the company's regional footprint.
-
Emerging Centers showed robust performance with a 25% year-on-year growth, with the Kolkata center growing by 40% and the South Mumbai center by 28%.
-
The company is focusing on precision oncology and integrating research and academics, positioning itself at the forefront of cancer care innovation.
Negative Points
-
The EBITDA margin decreased from 18.5% in Q2 to 16.45% in Q3, primarily due to seasonal factors and reduced operating leverage.
-
The South Mumbai center faced challenges in international business due to geopolitical issues, impacting its performance.
-
The Milann business continues to face revenue decline, partly due to competition from the original founder's new centers.
-
International patient business was affected by geopolitical tensions, particularly with Bangladesh, impacting medical tourism revenue.
-
The company anticipates losses from new brownfield centers in Bangalore, which may offset some of the EBITDA margin expansion.